Thiotepa
- Generic Name
- Thiotepa
- Brand Names
- Tepadina, Thiotepa Riemser
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N3PS
- CAS Number
- 52-24-4
- Unique Ingredient Identifier
- 905Z5W3GKH
- Background
N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow transplantation. It...
- Indication
ThioTEPA is used a as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients. Also, when high dose chemotherapy with HPCT support it is appropriate for the treatment of solid tumours in adult and paediatric patients.
- Associated Conditions
- Adenocarcinoma of the Ovaries, Breast Adenocarcinoma, Papillary transitional cell carcinoma of bladder, Malignant effusion
- Associated Therapies
- -
Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2014-05-29
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 61
- Registration Number
- NCT00202917
- Locations
- 🇩🇪
Center for Marrow Transplantation, Essen, Germany
🇩🇪University of Wuerzburg Medical Center, Wuerzburg, Germany
🇩🇪Deutsche Klinik für Diagnostik, Wiesbaden, Germany
Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 32
- Registration Number
- NCT00182793
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
- Conditions
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2010-09-21
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT00112567
- Locations
- 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
- First Posted Date
- 2005-03-04
- Last Posted Date
- 2016-12-15
- Lead Sponsor
- Yale University
- Target Recruit Count
- 20
- Registration Number
- NCT00104975
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia in Remission
- First Posted Date
- 2005-01-10
- Last Posted Date
- 2017-10-19
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Registration Number
- NCT00101140
Chemotherapy, Filgrastim, and Stem Cell Transplantation With Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer
- Conditions
- First Posted Date
- 2004-09-16
- Last Posted Date
- 2012-06-12
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT00004172
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
Biological Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer
- Conditions
- First Posted Date
- 2004-08-31
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- University of Illinois at Chicago
- Target Recruit Count
- 36
- Registration Number
- NCT00002616
- Locations
- 🇺🇸
University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States
Combination Chemotherapy in Treating Patients With Acute B-Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
- First Posted Date
- 2004-08-30
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00002471
- Locations
- 🇺🇸
Kaplan Cancer Center, New York, New York, United States
🇺🇸University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Standard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer
- Conditions
- First Posted Date
- 2004-08-24
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- Scottish Cancer Therapy Network
- Target Recruit Count
- 600
- Registration Number
- NCT00002755
- Locations
- 🇬🇧
St. James's Hospital, Leeds, England, United Kingdom
🇬🇧Addenbrooke's NHS Trust, Cambridge, England, United Kingdom
🇬🇧Cheltenham General Hospital, Cheltenham, England, United Kingdom
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2004-08-23
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- Hackensack Meridian Health
- Registration Number
- NCT00004906
- Locations
- 🇺🇸
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Ireland Cancer Center, Cleveland, Ohio, United States
🇺🇸Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.